ERAS

ERAS

USD

Erasca Inc. Common Stock

$1.520-0.060 (-3.797%)

Precio en Tiempo Real

Healthcare
Biotecnología
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$1.580

Máximo

$1.615

Mínimo

$1.515

Volumen

1.46M

Fundamentos de la Empresa

Capitalización de Mercado

430.6M

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

1.73M

Bolsa

NMS

Moneda

USD

Rango de 52 Semanas

Mínimo $1.01Actual $1.520Máximo $3.45

Noticias Relacionadas

Analyst Upgrades

Raymond James Initiates Coverage On Erasca with Outperform Rating, Announces Price Target of $5

Raymond James analyst Laura Prendergast initiates coverage on Erasca with a Outperform rating and announces Price Target of $5.

Ver más
Raymond James Initiates Coverage On Erasca with Outperform Rating, Announces Price Target of $5
GlobeNewswire

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex inhibitors,

Ver más
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
Analyst Upgrades

Goldman Sachs Maintains Buy on Erasca, Lowers Price Target to $3

Goldman Sachs analyst Chris Shibutani maintains Erasca with a Buy and lowers the price target from $3.5 to $3.

Ver más
Goldman Sachs Maintains Buy on Erasca, Lowers Price Target to $3
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Erasca, Maintains $6 Price Target

HC Wainwright & Co. analyst Andres Maldonado reiterates Erasca with a Buy and maintains $6 price target.

Ver más
HC Wainwright & Co. Reiterates Buy on Erasca, Maintains $6 Price Target
Analyst Upgrades

Morgan Stanley Assumes Erasca at Overweight, Maintains Price Target of $4

Morgan Stanley analyst Jeffrey Hung assumes Erasca with a Overweight rating and maintains Price Target of $4.

Ver más
Morgan Stanley Assumes Erasca at Overweight, Maintains Price Target of $4

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.